KHẢO SÁT THỰC TRẠNG SỬ DỤNG THUỐC ỨC CHẾ SGLT2 Ở BỆNH NHÂN SUY TIM CÓ PHÂN SUẤT TỐNG MÁU GIẢM ĐIỀU TRỊ NỘI TRÚ TẠI BỆNH VIỆN HỮU NGHỊ

Abstract

Objectives: Survey on the current status of SGLT2 inhibitor use in heart failure patients with reduced ejection fraction treated as inpatients at Huu Nghi Hospital. Method: Cross - sectional descriptive study. Results: - 72 patients with heart failure and reduced ejection fraction met the selection criteria. - Males accounted for 76.4%. - Patients had an average age of 78.0 ± 11.1 years; the oldest age was 95, the youngest was 50; most patients were 65 years old or older (93.1%). - 100% of patients had NT-pro BNP (pg/ml) >300. - Mean LVEF of patients was 35.1%. - The proportion of patients using SGLT2 inhibitors was 90.27%. - In the SGLT2 inhibitor group, 53.85% of patients used Dapagliflozin; 46.15% of patients used Empagliflozin. Conclusion: Most patients with heart failure with reduced ejection fraction have been treated with SGLT2 inhibitors.